| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6064288 | Journal of Allergy and Clinical Immunology | 2013 | 9 Pages |
Abstract
Omalizumab was well tolerated and reduced the signs and symptoms of CIU/CSU in patients who remained symptomatic despite the use of H1-antihistamines (up to 4 times the approved dose) plus H2-antihistamines, leukotriene receptor antagonists, or both.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Allen MD, Dennis MD, Mark PhD, Janice MD, FRCPC, James L. PhD, Edward MD, Joachim MD, Nikhil MD, Petra MD, Thilo MD, Robert G. MB, FRACP, Piotr MD, PhD, William MD, Marcus MD, Karin MD, PhD,